- Previous Close
0.0321 - Open
0.0310 - Bid 0.0305 x --
- Ask 0.0305 x --
- Day's Range
0.0305 - 0.0327 - 52 Week Range
0.0063 - 0.6100 - Volume
6,291,793 - Avg. Volume
22,926,028 - Market Cap (intraday)
12.863M - Beta (5Y Monthly) -2.10
- PE Ratio (TTM)
-- - EPS (TTM)
-0.1700 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Diagonal Bio AB (publ) operates as a biotechnology company in Sweden. The company offers LAMPlify, a customized system for general laboratory use to identify the presence of specific genetic markers for, for example, fungi, viruses, or bacteria. It is also involved in the development of PANVIRAL, a universal in vitro diagnostic system, that offers the potential for rapid and accurate point-of-care diagnoses in various settings, such as doctor's office, surgery, mobile clinics, hospital bedsides, and workplaces and airports. The company was incorporated in 2020 and is based in Lund, Sweden.
diagonalbio.comRecent News: DIABIO.ST
View MorePerformance Overview: DIABIO.ST
Trailing total returns as of 11/27/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: DIABIO.ST
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: DIABIO.ST
View MoreValuation Measures
Market Cap
12.86M
Enterprise Value
8.70M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
138.44
Price/Book (mrq)
0.46
Enterprise Value/Revenue
378.48
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-19.95%
Return on Equity (ttm)
-40.25%
Revenue (ttm)
1.21M
Net Income Avi to Common (ttm)
-10.2M
Diluted EPS (ttm)
-0.1700
Balance Sheet and Cash Flow
Total Cash (mrq)
1.73M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-14.55M